A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma
Inhibition of histone deacetylase (HDAC) provides a potential target for cancer treatment.
Histones are components of the core proteins of nucleosomes, and acetylation and
deacetylation of these proteins play a role in the regulation of gene expression. HDAC
activity is known to be increased in many types of malignant cells; HDAC inhibitors have
been shown to induce differentiation, cell cycle arrest, and apoptosis in cultured tumor
cells. Since this tumor-associated mechanism is common to many types of cancer, HDAC may
have a broad role in cancer treatment.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To Evaluate the Efficacy of LBH589 in the Treatment of Patients With Refractory Clear Cell Carcinoma, as Measured by Progression-free Survival
18 months
No
John D. Hainsworth, M.D.
Study Chair
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI GU 49
NCT00550277
January 2008
June 2010
Name | Location |
---|---|
Florida Cancer Specialists | Fort Myers, Florida 33901 |
Northeast Georgia Medical Center | Gainesville, Georgia 30501 |
Baton Rouge General Medical Center | Baton Rouge, Louisiana 70821-2511 |
Methodist Cancer Center | Omaha, Nebraska 68114 |
Peninsula Cancer Institute | Newport News, Virginia 23601 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |
Oncology Hematology Care | Cincinnati, Ohio 45242 |
Hematology Oncology Associates of Northern NJ | Morristown, New Jersey 07960 |
Chattanooga Oncology Hematology Associates | Chattanooga, Tennessee 37404 |